SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer

Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT) Follows recent appointments of Professor Ton Logtenberg as non-executive Chairman and Ray Barlow as Chief Executive Officer Dublin, Ireland, August 3, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment…

Read More

About

SynOx Therapeutics Limited is a late-stage clinical biopharmaceutical company registered in Ireland.

In November 2020, SynOx acquired from Roche an exclusive worldwide licence to emactuzumab, a potentially best-in-class CSF-1R therapeutic antibody.

Emactuzumab has a well-tolerated safety profile and showed remarkable efficacy in patients suffering from diffuse Tenosynovial Giant Cell Tumours (TGCT), a rare disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.